Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY).

Full DD Report for CLVLY

You must become a subscriber to view this report.

Recent News from (OTC: CLVLY)

CLINUVEL delivers second positive financial result
MELBOURNE, Australia, Aug. 29, 2018 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD ( ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced its annual financial results for the year ended 30 June 2018, with the Group achieving its second consecutive prof...
Source: GlobeNewswire
Date: August, 29 2018 06:52
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare genetic blood disorder known as erythropoietic protoporphyria (EPP). EPP patients suffer ext...
Source: GlobeNewswire
Date: June, 25 2018 06:00
CLINUVEL unveils new global positioning
MELBOURNE, Australia, Feb. 19, 2018 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA-DAX:UR9) (NASDAQ INTERNATIONAL DESIGNATION ADR:CLVLY) today released its new global Company positioning including the unveiling of a new Group identity and website. The global identity refl...
Source: GlobeNewswire
Date: February, 19 2018 22:47
Clinuvel: Turtle Or Race Horse? Both Have Their Qualities
Clinuvel Pharmaceuticals ( CLVLY ) held their annual general shareholder meeting on November 28th, 2017, publishing updates on product and application roadmaps ( Presentation slides ). Being blunt, the company disappointed many shareholders by a very ordinary presentation, as they had raised...
Source: SeekingAlpha
Date: December, 01 2017 11:23
Clinuvel: High Cash Returns - Catalysts For Growth Lined Up
It has been almost 10 months ago that I wrote my first article on Clinuvel (CLVLY) on Seeking Alpha, explaining my investment case and valuation approach. My fair value target in January 2017 was 21-28 USD/share (upside of 240-350%), supported by a discounted cash flow model. Back then, the ...
Source: SeekingAlpha
Date: November, 10 2017 17:11


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLVLY.

About Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY)

Logo for Clinuvel Pharmaceuticals Ltd. (OTC: CLVLY)

Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With our unique expertise in understanding the interaction of light and human skin, we have identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from , to million.


Contact Information



Current Management

  • Philippe Wolgen / CEO
  • Darren Keamy / CFO
  • Colin Mackie / Director, Bus. Dev.
  • Philippe Wolgen /

Current Share Structure

  • Market Cap: $212,671,970 - 03/15/2018
  • Issue and Outstanding: 30,381,710 - 12/31/2010


Daily Technical Chart for (OTC: CLVLY)

Daily Technical Chart for (OTC: CLVLY)

Stay tuned for daily updates and more on (OTC: CLVLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CLVLY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLVLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLVLY and does not buy, sell, or trade any shares of CLVLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: